{"id":3341,"date":"2023-10-23T12:15:05","date_gmt":"2023-10-23T12:15:05","guid":{"rendered":"http:\/\/rnce.inserm.fr\/statistics\/"},"modified":"2024-08-06T13:34:06","modified_gmt":"2024-08-06T13:34:06","slug":"statistics","status":"publish","type":"page","link":"https:\/\/rnce.inserm.fr\/en\/statistics\/","title":{"rendered":"Statistics"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3341\" class=\"elementor elementor-3341 elementor-51\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cc5a800 e-flex e-con-boxed e-con e-child\" data-id=\"cc5a800\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e6d5681 elementor-widget elementor-widget-text-editor\" data-id=\"e6d5681\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 05-08-2024 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">Childhood cancer is a rare disease, affecting approximately 1,800 children under the age of 15 each year in metropolitan France (about one newborn out of 440 will be diagnosed with cancer before the age of 15).<\/p>\n<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">The distribution of childhood cancers by histological type and location is very different from that of adults, notably with very few carcinomas. This is why incidence and survival are described according to a specific classification, the<a style=\"color: #537eb9;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15712273\" target=\"_blank\" rel=\"noopener\">International Classification of Childhood Cancer (ICCC), 3rd version<\/a>.<\/p>\n<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\"><a href=\"https:\/\/www.e-cancer.fr\/Patients-et-proches\/Les-cancers\/Les-cancers-chez-l-enfant\/Les-cancers-de-l-enfant\"><em>These figures are also available on the INCa website.<\/em><\/a><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d5fa547 elementor-widget elementor-widget-heading\" data-id=\"d5fa547\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 05-08-2024 *\/\n.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}<\/style><h3 class=\"elementor-heading-title elementor-size-default\">Incidence statistics<\/h3>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5b17fa8 elementor-widget elementor-widget-text-editor\" data-id=\"5b17fa8\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">The crude incidence rate for a given period and age group is estimated by dividing the number of new cases in this age group during this period by the number of people in this age group in the French population during this period.<\/p>\n<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">The direct standardization method was used to estimate the age-standardized incidence rate (ASR: Aged Standardised incidence Ratio), i.e. the incidence rate one would expect to find in the population if it had the same age composition as a standard &#8220;reference&#8221; population. The reference age structure is that of the world population, which assigns weights of, respectively, to the age groups, &lt;1 year, 1-4 years, 5-9 years, 10-14 years (Waterhouse J et al. eds. Cancer incidence in five continents, Lyon, IARC, 1976).<\/p>\n<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">The cumulative incidence rate, which measures the risk of developing cancer between birth and age 15, was estimated from crude incidence rates by age group.<\/p>\n<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">The temporal evolution of childhood cancer incidence, in particular the estimation of the percentage mean annual variation (MAV), was assessed using a Poisson regression model.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"dce-fix-background-loop elementor-element elementor-element-f733185 elementor-widget elementor-widget-dce-acf-repeater-v2\" data-id=\"f733185\" data-element_type=\"widget\" data-settings=\"{&quot;dce_acf_repeater_format&quot;:&quot;accordion&quot;,&quot;dce_acf_repeater_accordion_start&quot;:&quot;none&quot;,&quot;accordion_speed&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:300,&quot;sizes&quot;:[]}}\" data-widget_type=\"dce-acf-repeater-v2.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<div class=\"dce-acf-repeater\">\t\t\t\t\t<ul class=\"accordion\">\n\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><\/span>\n\t\t<span class=\"accordion-title\">\n\t\t\tAnnual average number of cases (N), crude, standardized, and cumulative annual incidence rates per million, and sex ratio of childhood cancers in metropolitan France (2014-2020*)\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-1bd15b1\">5585<\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><\/span>\n\t\t<span class=\"accordion-title accordion-title\">\n\t\t\tAverage annual number of cases (N), crude, standardized, and cumulative annual incidence rates per million up to 15 years old, and sex ratio of childhood cancers in metropolitan France (2014-2020*).\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-1bd15b1\"><table><thead><th><\/th><th>< 1 y<\/th><th><\/th><th>1-4 y<\/th><th><\/th><th>5-9 y<\/th><th><\/th><th>10-14 y <\/th><th><\/th><th>15-17 y<\/th><th><\/th><\/thead><tbody><tr><td><\/td><td>N\/y<\/td><td>IR<\/td><td>N\/y<\/td><td>IR<\/td><td>N\/y<\/td><td>IR<\/td><td>N\/y<\/td><td>IR<\/td><td>N\/y<\/td><td>IR<\/td><\/tr><tr><td>I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases<\/td><td>28<\/td><td>39,5<\/td><td>221<\/td><td>74,4<\/td><td>151<\/td><td>37,9<\/td><td>111<\/td><td>27,7<\/td><td>68<\/td><td>28,2<\/td><\/tr><tr><td>Ia. Lymphoid leukemias<\/td><td>11<\/td><td>15,2<\/td><td>192<\/td><td>64,5<\/td><td>123<\/td><td>30,9<\/td><td>79<\/td><td>19,6<\/td><td>43<\/td><td>18<\/td><\/tr><tr><td>Ib. Acute myeloid leukemias<\/td><td>10<\/td><td>14,6<\/td><td>22<\/td><td>7,5<\/td><td>20<\/td><td>5<\/td><td>22<\/td><td>5,5<\/td><td>15<\/td><td>6,2<\/td><\/tr><tr><td>II. Lymphomas and reticuloendothelial neoplasms<\/td><td>3<\/td><td>4,9<\/td><td>22<\/td><td>7,3<\/td><td>59<\/td><td>14,8<\/td><td>116<\/td><td>29<\/td><td>129<\/td><td>53,8<\/td><\/tr><tr><td>IIa. Hodgkin lymphomas<\/td><td>0<\/td><td>0<\/td><td>2<\/td><td>0,6<\/td><td>17<\/td><td>4,4<\/td><td>73<\/td><td>18,2<\/td><td>99<\/td><td>41,2<\/td><\/tr><tr><td>IIb. Non-Hodgkin lymphomas (except Burkitt lymphomas)<\/td><td>1<\/td><td>1,2<\/td><td>7<\/td><td>2,5<\/td><td>17<\/td><td>4,4<\/td><td>29<\/td><td>7,2<\/td><td>24<\/td><td>10,2<\/td><\/tr><tr><td>IIc. Burkitt lymphomas<\/td><td>0<\/td><td>0,2<\/td><td>10<\/td><td>3,2<\/td><td>24<\/td><td>6<\/td><td>13<\/td><td>3,2<\/td><td>4<\/td><td>1,7<\/td><\/tr><tr><td>III. CNS and miscellaneous intracranial and intraspinal neoplasms<\/td><td>25<\/td><td>35,6<\/td><td>151<\/td><td>50,6<\/td><td>168<\/td><td>42,2<\/td><td>142<\/td><td>35,3<\/td><td>75<\/td><td>31,2<\/td><\/tr><tr><td>IIIa. Ependymomas and choroid plexus tumors<\/td><td>4<\/td><td>6,3<\/td><td>19<\/td><td>6,3<\/td><td>10<\/td><td>2,4<\/td><td>7<\/td><td>1,9<\/td><td>6<\/td><td>2,5<\/td><\/tr><tr><td>IIIb. Astrocytomas<\/td><td>8<\/td><td>11,3<\/td><td>65<\/td><td>21,7<\/td><td>58<\/td><td>14,5<\/td><td>47<\/td><td>11,8<\/td><td>23<\/td><td>9,7<\/td><\/tr><tr><td>IIIc. Intracranial and intraspinal embryonal tumors<\/td><td>6<\/td><td>8,7<\/td><td>34<\/td><td>11,4<\/td><td>32<\/td><td>8<\/td><td>17<\/td><td>4,1<\/td><td>6<\/td><td>2,4<\/td><\/tr><tr><td>IIId. Other gliomas<\/td><td>3<\/td><td>3,6<\/td><td>16<\/td><td>5,3<\/td><td>32<\/td><td>8,1<\/td><td>22<\/td><td>5,6<\/td><td>10<\/td><td>4,1<\/td><\/tr><tr><td>IIIe. Other specified intracranial and intraspinal neoplasms<\/td><td>3<\/td><td>4,3<\/td><td>15<\/td><td>5<\/td><td>34<\/td><td>8,6<\/td><td>46<\/td><td>11,5<\/td><td>29<\/td><td>12,1<\/td><\/tr><tr><td>IV. Neuroblastomas and other peripheral nervous cell tumors<\/td><td>47<\/td><td>66<\/td><td>60<\/td><td>20,2<\/td><td>17<\/td><td>4,2<\/td><td>6<\/td><td>1,5<\/td><td>2<\/td><td>0,9<\/td><\/tr><tr><td>IVa. Neuroblastomas and ganglioneuroblastomas<\/td><td>47<\/td><td>66<\/td><td>60<\/td><td>20,1<\/td><td>16<\/td><td>4,1<\/td><td>4<\/td><td>1<\/td><td>1<\/td><td>0,5<\/td><\/tr><tr><td>V. Retinoblastomas<\/td><td>21<\/td><td>29,3<\/td><td>27<\/td><td>8,9<\/td><td>3<\/td><td>0,7<\/td><td>0<\/td><td>0<\/td><td>0<\/td><td>0<\/td><\/tr><tr><td>VI. Renal tumors<\/td><td>12<\/td><td>17<\/td><td>55<\/td><td>18,6<\/td><td>19<\/td><td>4,7<\/td><td>6<\/td><td>1,5<\/td><td>3<\/td><td>1,3<\/td><\/tr><tr><td>VIa. Nephroblastomas and other nonepithelial renal tumors<\/td><td>12<\/td><td>17<\/td><td>55<\/td><td>18,4<\/td><td>18<\/td><td>4,5<\/td><td>3<\/td><td>0,8<\/td><td>1<\/td><td>0,4<\/td><\/tr><tr><td>VII. Hepatic tumors<\/td><td>6<\/td><td>7,9<\/td><td>9<\/td><td>3<\/td><td>3<\/td><td>0,7<\/td><td>2<\/td><td>0,5<\/td><td>2<\/td><td>1<\/td><\/tr><tr><td>VIIa. Hepatoblastomas<\/td><td>5<\/td><td>7,3<\/td><td>8<\/td><td>2,8<\/td><td>2<\/td><td>0,6<\/td><td>1<\/td><td>0,1<\/td><td>0<\/td><td>0,1<\/td><\/tr><tr><td>VIII. Malignant bone tumors<\/td><td>1<\/td><td>1,6<\/td><td>4<\/td><td>1,4<\/td><td>23<\/td><td>5,8<\/td><td>61<\/td><td>15,1<\/td><td>41<\/td><td>17,3<\/td><\/tr><tr><td>VIIIa. Osteosarcomas<\/td><td>0<\/td><td>0<\/td><td>1<\/td><td>0,3<\/td><td>9<\/td><td>2,4<\/td><td>32<\/td><td>8,1<\/td><td>22<\/td><td>9,2<\/td><\/tr><tr><td>VIIIc. Ewing tumors and related bone sarcomas<\/td><td>1<\/td><td>1,2<\/td><td>3<\/td><td>0,9<\/td><td>12<\/td><td>3,1<\/td><td>26<\/td><td>6,4<\/td><td>16<\/td><td>6,8<\/td><\/tr><tr><td>IX. Soft tissue and other extraosseous sarcomas<\/td><td>11<\/td><td>15,4<\/td><td>33<\/td><td>11<\/td><td>30<\/td><td>7,5<\/td><td>33<\/td><td>8,2<\/td><td>26<\/td><td>11<\/td><\/tr><tr><td>IXa. Rhabdomyosarcomas<\/td><td>4<\/td><td>6,1<\/td><td>25<\/td><td>8,3<\/td><td>18<\/td><td>4,6<\/td><td>12<\/td><td>2,9<\/td><td>11<\/td><td>4,6<\/td><\/tr><tr><td>IXb. Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms<\/td><td>3<\/td><td>3,6<\/td><td>1<\/td><td>0,3<\/td><td>2<\/td><td>0,5<\/td><td>3<\/td><td>0,8<\/td><td>3<\/td><td>1,3<\/td><\/tr><tr><td>IXd. Other specified soft tissue sarcomas<\/td><td>3<\/td><td>4,9<\/td><td>6<\/td><td>1,9<\/td><td>7<\/td><td>1,8<\/td><td>14<\/td><td>3,6<\/td><td>10<\/td><td>4,1<\/td><\/tr><tr><td>IXe. Unspecified soft tissue sarcomas<\/td><td>1<\/td><td>0,8<\/td><td>1<\/td><td>0,4<\/td><td>2<\/td><td>0,6<\/td><td>4<\/td><td>1<\/td><td>2<\/td><td>0,8<\/td><\/tr><tr><td>X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads<\/td><td>14<\/td><td>19,6<\/td><td>10<\/td><td>3,3<\/td><td>12<\/td><td>3,1<\/td><td>28<\/td><td>6,9<\/td><td>30<\/td><td>12,7<\/td><\/tr><tr><td>Xa. Intracranial and intraspinal germ cell tumors<\/td><td>1<\/td><td>1,6<\/td><td>3<\/td><td>1,1<\/td><td>7<\/td><td>1,8<\/td><td>13<\/td><td>3,1<\/td><td>6<\/td><td>2,5<\/td><\/tr><tr><td>Xb. Malignant extracranial and extragonadal germ cell tumors<\/td><td>11<\/td><td>15,6<\/td><td>4<\/td><td>1,3<\/td><td>0<\/td><td>0,1<\/td><td>0<\/td><td>0,1<\/td><td>2<\/td><td>0,8<\/td><\/tr><tr><td>Xc. Malignant gonadal germ cell tumors<\/td><td>2<\/td><td>2,2<\/td><td>3<\/td><td>1<\/td><td>5<\/td><td>1,2<\/td><td>13<\/td><td>3,2<\/td><td>21<\/td><td>9<\/td><\/tr><tr><td>XI. Other malignant epithelial neoplasms and malignant melanomas<\/td><td>1<\/td><td>1,4<\/td><td>6<\/td><td>1,9<\/td><td>14<\/td><td>3,6<\/td><td>44<\/td><td>11<\/td><td>65<\/td><td>27,1<\/td><\/tr><tr><td>XIb. Thyroid carcinomas<\/td><td>0<\/td><td>0,6<\/td><td>1<\/td><td>0,3<\/td><td>4<\/td><td>1,1<\/td><td>18<\/td><td>4,4<\/td><td>34<\/td><td>14,3<\/td><\/tr><tr><td>XId. Malignant melanomas<\/td><td>0<\/td><td>0<\/td><td>2<\/td><td>0,7<\/td><td>3<\/td><td>0,6<\/td><td>4<\/td><td>0,9<\/td><td>8<\/td><td>3,2<\/td><\/tr><tr><td>XII. Other and unspecified malignant neoplasms<\/td><td>2<\/td><td>2,2<\/td><td>3<\/td><td>1<\/td><td>0<\/td><td>0,1<\/td><td>1<\/td><td>0,3<\/td><td>1<\/td><td>0,5<\/td><\/tr><tr><td>Total<\/td><td>170<\/td><td>240,4<\/td><td>600<\/td><td>201,6<\/td><td>498<\/td><td>125,1<\/td><td>550<\/td><td>137,2<\/td><td>443<\/td><td>185,1<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Annual number of cases (N), age specific annual incidence rates (IR), mainland France 2014-2020.<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><\/span>\n\t\t<span class=\"accordion-title accordion-title accordion-title\">\n\t\t\tAverage annual number of cases (N), specific annual incidence rate per million children (TI), by age group of childhood cancers in metropolitan France (2014-2020*).\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-1bd15b1\"><table><thead><th>Diagnostic groups and subgroups<\/th><th>N<\/th><th>Crude<\/th><th>ASR<\/th><th>Cumulative<\/th><th>Sex ratio<\/th><\/thead><tbody><tr><td>I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases<\/td><td>511<\/td><td>43,8<\/td><td>46,4<\/td><td>664,9<\/td><td>1,2<\/td><\/tr><tr><td>Ia. Lymphoid leukemias<\/td><td>404<\/td><td>34,6<\/td><td>36,8<\/td><td>525,6<\/td><td>1,2<\/td><\/tr><tr><td>Ib. Acute myeloid leukemias<\/td><td>75<\/td><td>6,4<\/td><td>6,7<\/td><td>97,1<\/td><td>1,1<\/td><\/tr><tr><td>Ic. Chronic myeloproliferative diseases<\/td><td>9<\/td><td>0,8<\/td><td>0,7<\/td><td>11,9<\/td><td>1<\/td><\/tr><tr><td>Id. Myelodysplastic syndromes and other myeloproliferative diseases<\/td><td>16<\/td><td>1,4<\/td><td>1,6<\/td><td>21,7<\/td><td>1,4<\/td><\/tr><tr><td>Ie. Unspecified and other specified leukemias<\/td><td>7<\/td><td>0,6<\/td><td>0,6<\/td><td>8,7<\/td><td>1,3<\/td><\/tr><tr><td>II. Lymphomas and reticuloendothelial neoplasms<\/td><td>200<\/td><td>17,2<\/td><td>15,8<\/td><td>253,1<\/td><td>1,8<\/td><\/tr><tr><td>IIa. Hodgkin lymphomas<\/td><td>92<\/td><td>7,9<\/td><td>6,9<\/td><td>115,4<\/td><td>1,3<\/td><\/tr><tr><td>IIb. Non-Hodgkin lymphomas (except Burkitt lymphomas)<\/td><td>55<\/td><td>4,7<\/td><td>4,4<\/td><td>69,2<\/td><td>1,7<\/td><\/tr><tr><td>IIc. Burkitt lymphomas<\/td><td>46<\/td><td>4<\/td><td>3,9<\/td><td>59<\/td><td>4,9<\/td><\/tr><tr><td>IId. Miscellaneous lymphoreticular neoplasms<\/td><td>6<\/td><td>0,6<\/td><td>0,6<\/td><td>8,4<\/td><td>0,8<\/td><\/tr><tr><td>IIe. Unspecified lymphomas<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1<\/td><td>0,5<\/td><\/tr><tr><td>III. CNS and miscellaneous intracranial and intraspinal neoplasms<\/td><td>485<\/td><td>41,6<\/td><td>42,3<\/td><td>625,3<\/td><td>1,1<\/td><\/tr><tr><td>IIIa. Ependymomas and choroid plexus tumors<\/td><td>40<\/td><td>3,5<\/td><td>3,8<\/td><td>53<\/td><td>1,3<\/td><\/tr><tr><td>IIIb. Astrocytomas<\/td><td>178<\/td><td>15,2<\/td><td>15,7<\/td><td>229,6<\/td><td>0,9<\/td><\/tr><tr><td>IIIc. Intracranial and intraspinal embryonal tumors<\/td><td>89<\/td><td>7,6<\/td><td>8<\/td><td>114,8<\/td><td>1,4<\/td><\/tr><tr><td>IIId. Other gliomas<\/td><td>73<\/td><td>6,3<\/td><td>6,2<\/td><td>93,3<\/td><td>1<\/td><\/tr><tr><td>IIIe. Other specified intracranial and intraspinal neoplasms<\/td><td>98<\/td><td>8,4<\/td><td>8<\/td><td>124,8<\/td><td>1,1<\/td><\/tr><tr><td>IIIf. Unspecified intracranial and intraspinal neoplasms<\/td><td>7<\/td><td>0,6<\/td><td>0,7<\/td><td>9,6<\/td><td>1,3<\/td><\/tr><tr><td>IV. Neuroblastomas and other peripheral nervous cell tumors<\/td><td>129<\/td><td>11,1<\/td><td>13,1<\/td><td>175,3<\/td><td>1<\/td><\/tr><tr><td>IVa. Neuroblastomas and ganglioneuroblastomas<\/td><td>126<\/td><td>10,8<\/td><td>12,9<\/td><td>171,9<\/td><td>1<\/td><\/tr><tr><td>IVb. Other peripheral nervous cell tumors<\/td><td>3<\/td><td>0,2<\/td><td>0,2<\/td><td>3,4<\/td><td>0,8<\/td><\/tr><tr><td>V. Retinoblastomas<\/td><td>50<\/td><td>4,3<\/td><td>5,2<\/td><td>68,4<\/td><td>1<\/td><\/tr><tr><td>VI. Renal tumors<\/td><td>92<\/td><td>7,9<\/td><td>9<\/td><td>122,4<\/td><td>0,7<\/td><\/tr><tr><td>VIa. Nephroblastomas and other nonepithelial renal tumors<\/td><td>88<\/td><td>7,5<\/td><td>8,7<\/td><td>117,1<\/td><td>0,7<\/td><\/tr><tr><td>VIb. Renal carcinomas<\/td><td>4<\/td><td>0,3<\/td><td>0,3<\/td><td>4,9<\/td><td>0,8<\/td><\/tr><tr><td>VIc. Unspecified malignant renal tumors<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>VII. Hepatic tumors<\/td><td>19<\/td><td>1,6<\/td><td>1,9<\/td><td>25,9<\/td><td>1,8<\/td><\/tr><tr><td>VIIa. Hepatoblastomas<\/td><td>17<\/td><td>1,4<\/td><td>1,7<\/td><td>22<\/td><td>1,8<\/td><\/tr><tr><td>VIIb. Hepatic carcinomas<\/td><td>2<\/td><td>0,2<\/td><td>0,2<\/td><td>3,3<\/td><td>1,8<\/td><\/tr><tr><td>VIIc. Unspecified malignant hepatic tumors<\/td><td>0<\/td><td>0<\/td><td>0<\/td><td>0,2<\/td><td>0<\/td><\/tr><tr><td>VIII. Malignant bone tumors<\/td><td>89<\/td><td>7,6<\/td><td>6,8<\/td><td>111,7<\/td><td>1,1<\/td><\/tr><tr><td>VIIIa. Osteosarcomas<\/td><td>43<\/td><td>3,7<\/td><td>3,2<\/td><td>53,7<\/td><td>0,9<\/td><\/tr><tr><td>VIIIb. Chondrosarcomas<\/td><td>2<\/td><td>0,1<\/td><td>0,1<\/td><td>2,2<\/td><td>0,8<\/td><\/tr><tr><td>VIIIc. Ewing tumors and related bone sarcomas<\/td><td>41<\/td><td>3,5<\/td><td>3,2<\/td><td>52,3<\/td><td>1,5<\/td><\/tr><tr><td>VIIId. Other specified malignant bone tumors<\/td><td>3<\/td><td>0,2<\/td><td>0,2<\/td><td>3<\/td><td>1<\/td><\/tr><tr><td>VIIIe. Unspecified malignant bone tumors<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1,1<\/td><td>1,4<\/td><\/tr><tr><td>IX. Soft tissue and other extraosseous sarcomas<\/td><td>106<\/td><td>9,1<\/td><td>9,4<\/td><td>137,9<\/td><td>1,3<\/td><\/tr><tr><td>IXa. Rhabdomyosarcomas<\/td><td>59<\/td><td>5<\/td><td>5,4<\/td><td>76,8<\/td><td>1,2<\/td><\/tr><tr><td>IXb. Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms<\/td><td>9<\/td><td>0,7<\/td><td>0,8<\/td><td>11,3<\/td><td>1,4<\/td><\/tr><tr><td>IXc. Kaposi sarcomas<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>IXd. Other specified soft tissue sarcomas<\/td><td>31<\/td><td>2,6<\/td><td>2,6<\/td><td>39,5<\/td><td>1,4<\/td><\/tr><tr><td>IXe. Unspecified soft tissue sarcomas<\/td><td>8<\/td><td>0,7<\/td><td>0,7<\/td><td>10,4<\/td><td>1,3<\/td><\/tr><tr><td>X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads<\/td><td>64<\/td><td>5,4<\/td><td>5,5<\/td><td>82,8<\/td><td>0,7<\/td><\/tr><tr><td>Xa. Intracranial and intraspinal germ cell tumors<\/td><td>24<\/td><td>2<\/td><td>1,9<\/td><td>30,5<\/td><td>2,3<\/td><\/tr><tr><td>Xb. Malignant extracranial and extragonadal germ cell tumors<\/td><td>16<\/td><td>1,3<\/td><td>1,7<\/td><td>21,8<\/td><td>0,5<\/td><\/tr><tr><td>Xc. Malignant gonadal germ cell tumors<\/td><td>22<\/td><td>1,9<\/td><td>1,8<\/td><td>28,2<\/td><td>0,3<\/td><\/tr><tr><td>Xd. Gonadal carcinomas<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1<\/td><td>0<\/td><\/tr><tr><td>Xe. Other and unspecified malignant gonadal tumors<\/td><td>1<\/td><td>0,1<\/td><td>0,1<\/td><td>1,2<\/td><td>0,2<\/td><\/tr><tr><td>XI. Other malignant epithelial neoplasms and malignant melanomas<\/td><td>65<\/td><td>5,6<\/td><td>5<\/td><td>82<\/td><td>0,7<\/td><\/tr><tr><td>XIa. Adrenocortical carcinomas<\/td><td>4<\/td><td>0,3<\/td><td>0,4<\/td><td>5,2<\/td><td>0,7<\/td><\/tr><tr><td>XIb. Thyroid carcinomas<\/td><td>23<\/td><td>2<\/td><td>1,8<\/td><td>29,3<\/td><td>0,4<\/td><\/tr><tr><td>XIc. Nasopharyngeal carcinomas<\/td><td>4<\/td><td>0,3<\/td><td>0,3<\/td><td>5<\/td><td>3,2<\/td><\/tr><tr><td>XId. Malignant melanomas<\/td><td>8<\/td><td>0,7<\/td><td>0,7<\/td><td>10,3<\/td><td>0,8<\/td><\/tr><tr><td>XIe. Skin carcinomas<\/td><td>3<\/td><td>0,3<\/td><td>0,3<\/td><td>4,3<\/td><td>0,7<\/td><\/tr><tr><td>XIf. Other and unspecified carcinomas<\/td><td>22<\/td><td>1,9<\/td><td>1,6<\/td><td>27,5<\/td><td>0,8<\/td><\/tr><tr><td>XII. Other and unspecified malignant neoplasms<\/td><td>6<\/td><td>0,5<\/td><td>0,6<\/td><td>8,2<\/td><td>1<\/td><\/tr><tr><td>XIIa. Other specified malignant tumors<\/td><td>6<\/td><td>0,5<\/td><td>0,5<\/td><td>7,2<\/td><td>1<\/td><\/tr><tr><td>XIIb. Other unspecified malignant tumors<\/td><td>1<\/td><td>0<\/td><td>0<\/td><td>0,5<\/td><td>1<\/td><\/tr><tr><td>Total<\/td><td>1817<\/td><td>155,7<\/td><td>161,2<\/td><td>2355,5<\/td><td>1,1<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>ASR: age standardised incidence rate<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Annual number of cases (N), crude, age standardised and cumulative incidence rate of childhood cancer, and sex ratio (mainland France, 2014-2020).<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><\/span>\n\t\t<span class=\"accordion-title accordion-title accordion-title accordion-title\">\n\t\t\tTemporal variation in the incidence of childhood cancers in metropolitan France over the period 2000-2016.\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-1bd15b1\"><table><thead><th>Diagnostic groups and subgroups<\/th><th>N<\/th><th>AAPC (%)<\/th><th>CI95%<\/th><th>p<\/th><\/thead><tbody><tr><td>I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases<\/td><td>8\u00a0503<\/td><td>0.1<\/td><td>[-0.3;0.6]<\/td><td>0.51<\/td><\/tr><tr><td>I.a Lymphoid leukemias<\/td><td>6\u00a0678<\/td><td>0.3<\/td><td>[-0.2;0.8]<\/td><td>0.18<\/td><\/tr><tr><td>I.b Acute myeloid leukemias<\/td><td>1\u00a0231<\/td><td>-0.5<\/td><td>[-1.6;0.7]<\/td><td>0.43<\/td><\/tr><tr><td>II. Lymphomas and reticuloendothelial neoplasms<\/td><td>3\u00a0258<\/td><td>-0.4<\/td><td>[-1.1;0.3]<\/td><td>0.22<\/td><\/tr><tr><td>II.a Hodgkin lymphomas<\/td><td>1\u00a0480<\/td><td>0.5<\/td><td>[-0.5;1.6]<\/td><td>0.34<\/td><\/tr><tr><td>II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)<\/td><td>983<\/td><td>-0.7<\/td><td>[-2.0;0.6]<\/td><td>0.29<\/td><\/tr><tr><td>II.c Burkitt lymphomas<\/td><td>788<\/td><td>-1.9<\/td><td>[-3.3;-0.5]<\/td><td>< 0.01<\/td><\/tr><tr><td>III. CNS and miscellaneous intracranial and intraspinal neoplasms<\/td><td>7\u00a0500<\/td><td>1.2<\/td><td>[0.7;1.7]<\/td><td>< 0.01<\/td><\/tr><tr><td>III.a Ependymomas and choroid plexus tumors<\/td><td>709<\/td><td>0.5<\/td><td>[-1.0;2.0]<\/td><td>0.52<\/td><\/tr><tr><td>III.b Astrocytomas<\/td><td>2\u00a0798<\/td><td>1.3<\/td><td>[0.5;2.0]<\/td><td>< 0.01<\/td><\/tr><tr><td>III.c Intracranial and intraspinal embryonal tumors<\/td><td>1\u00a0422<\/td><td>0.0<\/td><td>[-1.1;1.0]<\/td><td>0.96<\/td><\/tr><tr><td>III.d Other gliomas<\/td><td>1\u00a0017<\/td><td>0.5<\/td><td>[-0.7;1.8]<\/td><td>0.40<\/td><\/tr><tr><td>III.e Other specified intracranial and intraspinal neoplasms<\/td><td>1\u00a0436<\/td><td>3.2<\/td><td>[2.1;4.3]<\/td><td>< 0.01<\/td><\/tr><tr><td>IV. Neuroblastomas and other peripheral nervous cell tumors<\/td><td>2\u00a0404<\/td><td>-0.5<\/td><td>[-1.3;0.3]<\/td><td>0.20<\/td><\/tr><tr><td>IV.a Neuroblastomas and ganglioneuroblastomas<\/td><td>2\u00a0372<\/td><td>-0.5<\/td><td>[-1.4;0.3]<\/td><td>0.19<\/td><\/tr><tr><td>V. Retinoblastomas<\/td><td>849<\/td><td>-0.4<\/td><td>[-1.8;1.0]<\/td><td>0.57<\/td><\/tr><tr><td>VI. Renal tumors<\/td><td>1\u00a0637<\/td><td>-0.5<\/td><td>[-1.5;0.5]<\/td><td>0.29<\/td><\/tr><tr><td>VI.a Nephroblastomas and other nonepithelial renal tumors<\/td><td>1\u00a0583<\/td><td>-0.4<\/td><td>[-1.4;0.6]<\/td><td>0.41<\/td><\/tr><tr><td>VII. Hepatic tumors<\/td><td>304<\/td><td>1.8<\/td><td>[-0.5;4.2]<\/td><td>0.12<\/td><\/tr><tr><td>VII.a Hepatoblastomas<\/td><td>256<\/td><td>2.0<\/td><td>[-0.6;4.6]<\/td><td>0.13<\/td><\/tr><tr><td>VIII. Malignant bone tumors<\/td><td>1\u00a0422<\/td><td>0.4<\/td><td>[-0.7;1.5]<\/td><td>0.47<\/td><\/tr><tr><td>VIII.a Osteosarcomas<\/td><td>660<\/td><td>-0.2<\/td><td>[-1.8;1.3]<\/td><td>0.78<\/td><\/tr><tr><td>VIII.c Ewing tumors and related bone sarcomas<\/td><td>657<\/td><td>1.6<\/td><td>[0.0;3.2]<\/td><td>0.05<\/td><\/tr><tr><td>IX. Soft tissue and other extraosseous sarcomas<\/td><td>1\u00a0882<\/td><td>-0.1<\/td><td>[-1.1;0.8]<\/td><td>0.76<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomas<\/td><td>1\u00a0019<\/td><td>0.0<\/td><td>[-1.3;1.2]<\/td><td>0.94<\/td><\/tr><tr><td>IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms<\/td><td>139<\/td><td>0.7<\/td><td>[-2.6;4.2]<\/td><td>0.68<\/td><\/tr><tr><td>IX.d Other specified soft tissue sarcomas<\/td><td>579<\/td><td>-0.5<\/td><td>[-2.2;1.1]<\/td><td>0.52<\/td><\/tr><tr><td>IX.e Unspecified soft tissue sarcomas<\/td><td>141<\/td><td>0.5<\/td><td>[-2.8;4.0]<\/td><td>0.76<\/td><\/tr><tr><td>X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads<\/td><td>1\u00a0113<\/td><td>-0.9<\/td><td>[-2.1;0.2]<\/td><td>0.12<\/td><\/tr><tr><td>X.a Intracranial and intraspinal germ cell tumors<\/td><td>423<\/td><td>0.0<\/td><td>[-1.9;2.0]<\/td><td>0.99<\/td><\/tr><tr><td>X.b Malignant extracranial and extragonadal germ cell tumors<\/td><td>291<\/td><td>-2.1<\/td><td>[-4.4;0.2]<\/td><td>0.08<\/td><\/tr><tr><td>X.c Malignant gonadal germ cell tumors<\/td><td>369<\/td><td>-1.3<\/td><td>[-3.3;0.8]<\/td><td>0.21<\/td><\/tr><tr><td>XI. Other malignant epithelial neoplasms and malignant melanomas<\/td><td>1\u00a0024<\/td><td>1.4<\/td><td>[0.1;2.7]<\/td><td>0.03<\/td><\/tr><tr><td>XI.b Thyroid carcinomas<\/td><td>411<\/td><td>-1.3<\/td><td>[-3.3;0.6]<\/td><td>0.19<\/td><\/tr><tr><td>XI.d Malignant melanomas<\/td><td>186<\/td><td>-1.2<\/td><td>[-4.0;1.8]<\/td><td>0.44<\/td><\/tr><tr><td>XII. Other and unspecified malignant neoplasms<\/td><td>70<\/td><td>4.8<\/td><td>[-0.2;10.0]<\/td><td>0.06<\/td><\/tr><tr><td>All cancers (excluding Langherhans cell histiocytosis)<\/td><td>29\u00a0966<\/td><td>0.3<\/td><td>[0.0;0.5]<\/td><td>0.03<\/td><\/tr><tr><td>Langherhans cell histiocytosis<\/td><td>118<\/td><td>-1.0<\/td><td>[-4.6;2.7]<\/td><td>0.6<\/td><\/tr><tr><td>All cancers (including Langherhans cell histiocytosis)<\/td><td>30\u00a0084<\/td><td>0.3<\/td><td>[0.0;0.5]<\/td><td>0.03<\/td><\/tr><tr><td>AAPC: average annual percent change in incidence rate (estimated by Poisson regression model)<\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li><\/ul><\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dcefb08 elementor-widget elementor-widget-heading\" data-id=\"dcefb08\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Survival statistics<\/h3>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-95447a1 elementor-widget elementor-widget-text-editor\" data-id=\"95447a1\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">Overall survival was estimated by the Kaplan-Meier method, using Greenwood&#8217;s variance formula. The survival curves of the different groups were compared using the Log-rank test.<\/p>\n<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">Over the period 2000-2014, 26,124 cases of pediatric cancers were recorded by the RNCE. The overall survival rate for these children is estimated at 92% one year after diagnosis, and 82% five years after diagnosis.<\/p>\n<p style=\"font-family: 'Open Sans', sans-serif; font-size: medium;\">Survival after childhood cancer improved between 2000 and 2014, from 81% to 83%, 5 years after diagnosis. This positive trend was observed for most diagnostic groups, notably leukemias (83% to 86%) and brain tumors (71% to 74%).  <\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"dce-fix-background-loop elementor-element elementor-element-0a00871 elementor-widget elementor-widget-dce-acf-repeater-v2\" data-id=\"0a00871\" data-element_type=\"widget\" data-settings=\"{&quot;dce_acf_repeater_format&quot;:&quot;accordion&quot;,&quot;dce_acf_repeater_accordion_start&quot;:&quot;none&quot;,&quot;accordion_speed&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:300,&quot;sizes&quot;:[]}}\" data-widget_type=\"dce-acf-repeater-v2.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<div class=\"dce-acf-repeater\">\t\t\t\t\t<ul class=\"accordion\">\n\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><\/span>\n\t\t<span class=\"accordion-title\">\n\t\t\tEstimation of 1-year, 2-year, and 5-year survival rates of childhood cancers in metropolitan France, by diagnostic group (2000-2016).\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-c6a9103\"><table><thead><th><\/th><th>Overall survival rates (IC95%)<\/th><th><\/th><th><\/th><th><\/th><th><\/th><th><\/th><th><\/th><\/thead><tbody><tr><td>Diagnostic groups and subgroups<\/td><td>N<\/td><td>1y-OS<\/td><td><\/td><td>2y-OS<\/td><td><\/td><td>5y-OS<\/td><td><\/td><\/tr><tr><td>I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases<\/td><td>8503<\/td><td>94.1<\/td><td>[93.6-94.6]<\/td><td>90.4<\/td><td>[89.7-91.0]<\/td><td>86.1<\/td><td>[85.3-86.8]<\/td><\/tr><tr><td>I.a Lymphoid leukemias<\/td><td>6678<\/td><td>96.4<\/td><td>[95.9-96.8]<\/td><td>93.8<\/td><td>[93.1-94.3]<\/td><td>90.0<\/td><td>[89.3-90.7]<\/td><\/tr><tr><td>I.b Acute myeloid leukemias<\/td><td>1231<\/td><td>84.6<\/td><td>[82.5-86.5]<\/td><td>76.6<\/td><td>[74.1-78.9]<\/td><td>70.2<\/td><td>[67.5-72.7]<\/td><\/tr><tr><td>II. Lymphomas and reticuloendothelial neoplasms<\/td><td>3258<\/td><td>96.9<\/td><td>[96.3-97.5]<\/td><td>95.4<\/td><td>[94.6-96.1]<\/td><td>94.3<\/td><td>[93.4-95.1]<\/td><\/tr><tr><td>II.a Hodgkin lymphomas<\/td><td>1480<\/td><td>99.6<\/td><td>[99.1-99.8]<\/td><td>98.8<\/td><td>[98.0-99.2]<\/td><td>97.7<\/td><td>[96.8-98.4]<\/td><\/tr><tr><td>II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)<\/td><td>983<\/td><td>94.6<\/td><td>[93.0-95.9]<\/td><td>91.4<\/td><td>[89.4-93.0]<\/td><td>89.5<\/td><td>[87.4-91.3]<\/td><\/tr><tr><td>II.c Burkitt lymphomas<\/td><td>788<\/td><td>94.9<\/td><td>[93.1-96.3]<\/td><td>94.3<\/td><td>[92.4-95.7]<\/td><td>94.0<\/td><td>[92.0-95.4]<\/td><\/tr><tr><td>III. CNS and miscellaneous intracranial and intraspinal neoplasms<\/td><td>7500<\/td><td>85.7<\/td><td>[84.9-86.5]<\/td><td>79.3<\/td><td>[78.4-80.2]<\/td><td>74.4<\/td><td>[73.4-75.4]<\/td><\/tr><tr><td>III.a Ependymomas and choroid plexus tumors<\/td><td>709<\/td><td>91.4<\/td><td>[89.0-93.2]<\/td><td>85.9<\/td><td>[83.1-88.2]<\/td><td>74.6<\/td><td>[71.1-77.8]<\/td><\/tr><tr><td>III.b Astrocytomas<\/td><td>2798<\/td><td>92.7<\/td><td>[91.7-93.6]<\/td><td>88.8<\/td><td>[87.6-89.9]<\/td><td>87.0<\/td><td>[85.6-88.2]<\/td><\/tr><tr><td>III.c Intracranial and intraspinal embryonal tumors<\/td><td>1422<\/td><td>75.4<\/td><td>[73.1-77.6]<\/td><td>66.0<\/td><td>[63.4-68.4]<\/td><td>55.7<\/td><td>[53.0-58.4]<\/td><\/tr><tr><td>III.d Other gliomas<\/td><td>1017<\/td><td>62.3<\/td><td>[59.2-65.2]<\/td><td>44.8<\/td><td>[41.7-47.8]<\/td><td>38.7<\/td><td>[35.6-41.7]<\/td><\/tr><tr><td>III.e Other specified intracranial and intraspinal neoplasms<\/td><td>1436<\/td><td>97.7<\/td><td>[96.8-98.4]<\/td><td>96.5<\/td><td>[95.4-97.4]<\/td><td>95.3<\/td><td>[94.1-96.3]<\/td><\/tr><tr><td>IV. Neuroblastomas and other peripheral nervous cell tumors<\/td><td>2404<\/td><td>92.0<\/td><td>[90.8-93.0]<\/td><td>85.6<\/td><td>[84.1-86.9]<\/td><td>76.4<\/td><td>[74.6-78.1]<\/td><\/tr><tr><td>IV.a Neuroblastomas and ganglioneuroblastomas<\/td><td>2372<\/td><td>92.0<\/td><td>[90.8-93.0]<\/td><td>85.5<\/td><td>[84.0-86.9]<\/td><td>76.2<\/td><td>[74.4-77.9]<\/td><\/tr><tr><td>V. Retinoblastomas<\/td><td>849<\/td><td>99.5<\/td><td>[98.7-99.8]<\/td><td>99.5<\/td><td>[98.7-99.8]<\/td><td>99.3<\/td><td>[98.4-99.7]<\/td><\/tr><tr><td>VI. Renal tumors<\/td><td>1637<\/td><td>96.8<\/td><td>[95.8-97.6]<\/td><td>94.5<\/td><td>[93.3-95.5]<\/td><td>92.7<\/td><td>[91.3-93.9]<\/td><\/tr><tr><td>VI.a Nephroblastomas and other nonepithelial renal tumors<\/td><td>1583<\/td><td>97.0<\/td><td>[96.0-97.7]<\/td><td>94.8<\/td><td>[93.6-95.8]<\/td><td>93.0<\/td><td>[91.6-94.2]<\/td><\/tr><tr><td>VII. Hepatic tumors<\/td><td>304<\/td><td>90.4<\/td><td>[86.5-93.3]<\/td><td>86.5<\/td><td>[82.1-89.8]<\/td><td>83.1<\/td><td>[78.4-87.0]<\/td><\/tr><tr><td>VII.a Hepatoblastomas<\/td><td>256<\/td><td>91.0<\/td><td>[86.8-93.9]<\/td><td>86.3<\/td><td>[81.4-90.0]<\/td><td>85.4<\/td><td>[80.5-89.2]<\/td><\/tr><tr><td>VIII. Malignant bone tumors<\/td><td>1422<\/td><td>94.4<\/td><td>[93.1-95.5]<\/td><td>87.0<\/td><td>[85.1-88.6]<\/td><td>74.1<\/td><td>[71.7-76.4]<\/td><\/tr><tr><td>VIII.a Osteosarcomas<\/td><td>660<\/td><td>93.0<\/td><td>[90.8-94.7]<\/td><td>85.7<\/td><td>[82.7-88.1]<\/td><td>71.3<\/td><td>[67.5-74.7]<\/td><\/tr><tr><td>VIII.c Ewing tumors and related bone sarcomas<\/td><td>657<\/td><td>95.9<\/td><td>[94.1-97.2]<\/td><td>87.9<\/td><td>[85.2-90.2]<\/td><td>75.4<\/td><td>[71.8-78.7]<\/td><\/tr><tr><td>IX. Soft tissue and other extraosseous sarcomas<\/td><td>1882<\/td><td>90.2<\/td><td>[88.7-91.4]<\/td><td>81.8<\/td><td>[80.0-83.5]<\/td><td>72.5<\/td><td>[70.4-74.6]<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomas<\/td><td>1019<\/td><td>92.5<\/td><td>[90.7-94.0]<\/td><td>83.5<\/td><td>[81.0-85.6]<\/td><td>73.0<\/td><td>[70.1-75.7]<\/td><\/tr><tr><td>IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms<\/td><td>139<\/td><td>92.8<\/td><td>[87.0-96.1]<\/td><td>87.1<\/td><td>[80.2-91.6]<\/td><td>81.2<\/td><td>[73.3-86.9]<\/td><\/tr><tr><td>IX.d Other specified soft tissue sarcomas<\/td><td>579<\/td><td>86.2<\/td><td>[83.1-88.7]<\/td><td>79.4<\/td><td>[75.9-82.5]<\/td><td>70.9<\/td><td>[66.9-74.5]<\/td><\/tr><tr><td>IX.e Unspecified soft tissue sarcomas<\/td><td>141<\/td><td>86.5<\/td><td>[79.7-91.2]<\/td><td>74.4<\/td><td>[66.4-80.8]<\/td><td>66.8<\/td><td>[58.1-74.1]<\/td><\/tr><tr><td>X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads<\/td><td>1113<\/td><td>96.5<\/td><td>[95.2-97.4]<\/td><td>95.0<\/td><td>[93.5-96.1]<\/td><td>94.1<\/td><td>[92.5-95.3]<\/td><\/tr><tr><td>X.a Intracranial and intraspinal germ cell tumors<\/td><td>423<\/td><td>96.6<\/td><td>[94.4-98.0]<\/td><td>95.1<\/td><td>[92.6-96.8]<\/td><td>94.3<\/td><td>[91.6-96.2]<\/td><\/tr><tr><td>X.b Malignant extracranial and extragonadal germ cell tumors<\/td><td>291<\/td><td>93.5<\/td><td>[90.0-95.8]<\/td><td>92.1<\/td><td>[88.3-94.7]<\/td><td>90.9<\/td><td>[86.9-93.7]<\/td><\/tr><tr><td>X.c Malignant gonadal germ cell tumors<\/td><td>369<\/td><td>98.9<\/td><td>[97.1-99.6]<\/td><td>98.3<\/td><td>[96.4-99.3]<\/td><td>97.8<\/td><td>[95.6-98.9]<\/td><\/tr><tr><td>XI. Other malignant epithelial neoplasms and malignant melanomas<\/td><td>1024<\/td><td>96.5<\/td><td>[95.1-97.5]<\/td><td>95.0<\/td><td>[93.4-96.2]<\/td><td>93.3<\/td><td>[91.5-94.7]<\/td><\/tr><tr><td>XI.b Thyroid carcinomas<\/td><td>411<\/td><td>99.3<\/td><td>[97.7-99.8]<\/td><td>99.3<\/td><td>[97.7-99.8]<\/td><td>99.0<\/td><td>[97.3-99.6]<\/td><\/tr><tr><td>XI.d Malignant melanomas<\/td><td>186<\/td><td>92.3<\/td><td>[87.4-95.4]<\/td><td>91.2<\/td><td>[86.0-94.5]<\/td><td>87.4<\/td><td>[81.5-91.5]<\/td><\/tr><tr><td>XII. Other and unspecified malignant neoplasms<\/td><td>70<\/td><td>86.6<\/td><td>[75.8-92.8]<\/td><td>80.5<\/td><td>[68.9-88.2]<\/td><td>78.9<\/td><td>[67.0-86.9]<\/td><\/tr><tr><td>All cancers (excluding Langherhans cell histiocytosis)<\/td><td>29966<\/td><td>92.3<\/td><td>[92.0-92.6]<\/td><td>87.8<\/td><td>[87.4-88.2]<\/td><td>83.1<\/td><td>[82.6-83.5]<\/td><\/tr><tr><td>Langherhans cell histiocytosis<\/td><td>118<\/td><td>93.9<\/td><td>[87.7-97.1]<\/td><td>93.1<\/td><td>[86.6-96.5]<\/td><td>93.1<\/td><td>[86.6-96.5]<\/td><\/tr><tr><td>All cancers (including Langherhans cell histiocytosis)<\/td><td>30084<\/td><td>92.3<\/td><td>[92.0-92.6]<\/td><td>87.8<\/td><td>[87.4-88.2]<\/td><td>83.1<\/td><td>[82.7-83.5]<\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><\/span>\n\t\t<span class=\"accordion-title accordion-title\">\n\t\t\tEstimation of the 5-year survival rate of childhood cancers in metropolitan France, by diagnostic group and age group (2000-2016).\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-c6a9103\"><table><thead><th>Diagnostic groups and subgroups<\/th><th><\/th><th>OS < 1 year<\/th><th><\/th><th>OS 1-4 years<\/th><th><\/th><th>OS 5-9 years<\/th><th><\/th><th>OS 10-14 years<\/th><th><\/th><\/thead><tbody><tr><td>I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases<\/td><td>61.2<\/td><td>[56.6-65.5]<\/td><td>89.9<\/td><td>[88.8-90.8]<\/td><td>89.2<\/td><td>[87.9-90.4]<\/td><td>80.8<\/td><td>[78.8-82.5]<\/td><td>**<\/td><\/tr><tr><td>I.a Lymphoid leukemias<\/td><td>53.8<\/td><td>[46.4-60.7]<\/td><td>93.8<\/td><td>[92.9-94.6]<\/td><td>91.4<\/td><td>[90.1-92.6]<\/td><td>84.0<\/td><td>[81.9-86]<\/td><td>**<\/td><\/tr><tr><td>I.b Acute myeloid leukemias<\/td><td>66.1<\/td><td>[58.9-72.4]<\/td><td>66.9<\/td><td>[61.9-71.3]<\/td><td>80.8<\/td><td>[75.6-85.1]<\/td><td>67.6<\/td><td>[62.4-72.3]<\/td><td>**<\/td><\/tr><tr><td>II. Lymphomas and reticuloendothelial neoplasms<\/td><td>92.9<\/td><td>[59.1-99.0]<\/td><td>92.5<\/td><td>[89.3-94.8]<\/td><td>94.4<\/td><td>[92.7-95.7]<\/td><td>94.7<\/td><td>[93.5-95.6]<\/td><td><\/td><\/tr><tr><td>II.a Hodgkin lymphomas<\/td><td>-<\/td><td>-<\/td><td>100.0<\/td><td>-<\/td><td>98.6<\/td><td>[96.3-99.5]<\/td><td>97.4<\/td><td>[96.3-98.2]<\/td><td><\/td><\/tr><tr><td>II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)<\/td><td>90.9<\/td><td>[50.8-98.7]<\/td><td>86.4<\/td><td>[79.9-90.9]<\/td><td>89.9<\/td><td>[85.9-92.7]<\/td><td>90.3<\/td><td>[87.2-92.7]<\/td><td><\/td><\/tr><tr><td>II.c Burkitt lymphomas<\/td><td>100.0<\/td><td>-<\/td><td>96.0<\/td><td>[91.8-98.1]<\/td><td>95.1<\/td><td>[92.3-96.9]<\/td><td>90.4<\/td><td>[85.6-93.6]<\/td><td><\/td><\/tr><tr><td>III. CNS and miscellaneous intracranial and intraspinal neoplasms<\/td><td>62.7<\/td><td>[58.2-66.9]<\/td><td>72.9<\/td><td>[71-74.6]<\/td><td>72.4<\/td><td>[70.6-74.2]<\/td><td>81.4<\/td><td>[79.7-83.1]<\/td><td>**<\/td><\/tr><tr><td>III.a Ependymomas and choroid plexus tumors<\/td><td>70.5<\/td><td>[60.3-78.5]<\/td><td>67.9<\/td><td>[62.1-72.9]<\/td><td>79.9<\/td><td>[72.2-85.6]<\/td><td>86.9<\/td><td>[79.7-91.6]<\/td><td>**<\/td><\/tr><tr><td>III.b Astrocytomas<\/td><td>82.5<\/td><td>[75.1-87.8]<\/td><td>94.3<\/td><td>[92.6-95.5]<\/td><td>82.9<\/td><td>[80.3-85.3]<\/td><td>82.5<\/td><td>[79.4-85.1]<\/td><td>**<\/td><\/tr><tr><td>III.c Intracranial and intraspinal embryonal tumors<\/td><td>26.1<\/td><td>[18.7-34.1]<\/td><td>38.1<\/td><td>[33.8-42.3]<\/td><td>69.1<\/td><td>[64.6-73.1]<\/td><td>79.1<\/td><td>[73.3-83.8]<\/td><td>**<\/td><\/tr><tr><td>III.d Other gliomas<\/td><td>67.2<\/td><td>[50.3-79.5]<\/td><td>44.5<\/td><td>[38.2-50.5]<\/td><td>26.2<\/td><td>[22.0-30.6]<\/td><td>47.0<\/td><td>[41.3-52.6]<\/td><td>**<\/td><\/tr><tr><td>III.e Other specified intracranial and intraspinal neoplasms<\/td><td>84.2<\/td><td>[71.9-91.5]<\/td><td>94.2<\/td><td>[90.5-96.5]<\/td><td>95.6<\/td><td>[93.2-97.1]<\/td><td>96.7<\/td><td>[94.9-97.8]<\/td><td>**<\/td><\/tr><tr><td>IV. Neuroblastomas and other peripheral nervous cell tumors<\/td><td>90.7<\/td><td>[88.6-92.4]<\/td><td>67.2<\/td><td>[64.3-70.0]<\/td><td>66.1<\/td><td>[59.7-71.8]<\/td><td>71.4<\/td><td>[60.0-80.0]<\/td><td>**<\/td><\/tr><tr><td>IV.a Neuroblastomas and ganglioneuroblastomas<\/td><td>90.7<\/td><td>[88.7-92.5]<\/td><td>67.1<\/td><td>[64.2-69.9]<\/td><td>66.2<\/td><td>[59.7-71.9]<\/td><td>62.8<\/td><td>[49.4-73.6]<\/td><td>**<\/td><\/tr><tr><td>V. Retinoblastomas<\/td><td>99.5<\/td><td>[97.9-99.9]<\/td><td>99.0<\/td><td>[97.5-99.6]<\/td><td>100.0<\/td><td>-<\/td><td>100.0<\/td><td>-<\/td><td><\/td><\/tr><tr><td>VI. Renal tumors<\/td><td>88.3<\/td><td>[83.5-91.9]<\/td><td>94.3<\/td><td>[92.7-95.6]<\/td><td>93.2<\/td><td>[89.8-95.5]<\/td><td>81.9<\/td><td>[70.3-89.3]<\/td><td>**<\/td><\/tr><tr><td>VI.a Nephroblastomas and other nonepithelial renal tumors<\/td><td>88.3<\/td><td>[83.5-91.9]<\/td><td>94.3<\/td><td>[92.7-95.6]<\/td><td>93.3<\/td><td>[89.8-95.6]<\/td><td>85.0<\/td><td>[69.6-93.0]<\/td><td>**<\/td><\/tr><tr><td>VII. Hepatic tumors<\/td><td>89.9<\/td><td>[80.8-94.8]<\/td><td>87.3<\/td><td>[80.8-91.7]<\/td><td>74.4<\/td><td>[55.0-86.4]<\/td><td>62.4<\/td><td>[45.5-75.4]<\/td><td>**<\/td><\/tr><tr><td>VII.a Hepatoblastomas<\/td><td>89.7<\/td><td>[80.5-94.7]<\/td><td>87.5<\/td><td>[80.8-91.9]<\/td><td>74.6<\/td><td>[51.9-87.7]<\/td><td>44.4<\/td><td>[13.6-71.9]<\/td><td>**<\/td><\/tr><tr><td>VIII. Malignant bone tumors<\/td><td>85.7<\/td><td>[33.4-97.9]<\/td><td>74.2<\/td><td>[63.2-82.4]<\/td><td>75.2<\/td><td>[70.5-79.2]<\/td><td>73.6<\/td><td>[70.5-76.4]<\/td><td><\/td><\/tr><tr><td>VIII.a Osteosarcomas<\/td><td>100.0<\/td><td>-<\/td><td>57.1<\/td><td>[28.4-78.0]<\/td><td>71.1<\/td><td>[63.4-77.4]<\/td><td>71.7<\/td><td>[67.2-75.7]<\/td><td><\/td><\/tr><tr><td>VIII.c Ewing tumors and related bone sarcomas<\/td><td>80.0<\/td><td>[20.4-96.9]<\/td><td>78.4<\/td><td>[65.6-86.9]<\/td><td>77.4<\/td><td>[70.7-82.7]<\/td><td>73.9<\/td><td>[68.9-78.2]<\/td><td><\/td><\/tr><tr><td>IX. Soft tissue and other extraosseous sarcomas<\/td><td>69.8<\/td><td>[62.9-75.8]<\/td><td>75.2<\/td><td>[71.4-78.5]<\/td><td>75.3<\/td><td>[71.2-78.9]<\/td><td>68.2<\/td><td>[64.1-72.0]<\/td><td>**<\/td><\/tr><tr><td>IX.a Rhabdomyosarcomas<\/td><td>84.6<\/td><td>[73.3-91.4]<\/td><td>76.3<\/td><td>[71.9-80.0]<\/td><td>72.9<\/td><td>[67.5-77.6]<\/td><td>60.8<\/td><td>[53.1-67.6]<\/td><td>**<\/td><\/tr><tr><td>IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms<\/td><td>88.7<\/td><td>[76.5-94.7]<\/td><td>91.7<\/td><td>[53.9-98.8]<\/td><td>82.6<\/td><td>[60.0-93.1]<\/td><td>67.2<\/td><td>[50.7-79.3]<\/td><td><\/td><\/tr><tr><td>IX.d Other specified soft tissue sarcomas<\/td><td>39.0<\/td><td>[26.7-51.1]<\/td><td>72.7<\/td><td>[63.0-80.3]<\/td><td>79.2<\/td><td>[71.3-85.2]<\/td><td>72.6<\/td><td>[66.8-77.6]<\/td><td>**<\/td><\/tr><tr><td>IX.e Unspecified soft tissue sarcomas<\/td><td>56.3<\/td><td>[29.5-76.2]<\/td><td>49.7<\/td><td>[27.4-68.5]<\/td><td>74.5<\/td><td>[56.4-85.9]<\/td><td>71.0<\/td><td>[57.8-80.7]<\/td><td><\/td><\/tr><tr><td>X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads<\/td><td>91.3<\/td><td>[87.1-94.2]<\/td><td>96.3<\/td><td>[92.7-98.1]<\/td><td>96.9<\/td><td>[92.6-98.7]<\/td><td>93.5<\/td><td>[90.7-95.4]<\/td><td>*<\/td><\/tr><tr><td>X.a Intracranial and intraspinal germ cell tumors<\/td><td>91.6<\/td><td>[76.1-97.2]<\/td><td>93.4<\/td><td>[84.8-97.2]<\/td><td>95.6<\/td><td>[88.6-98.3]<\/td><td>94.5<\/td><td>[90.3-96.9]<\/td><td><\/td><\/tr><tr><td>X.b Malignant extracranial and extragonadal germ cell tumors<\/td><td>89.1<\/td><td>[83.5-92.9]<\/td><td>96.2<\/td><td>[88.6-98.8]<\/td><td>100.0<\/td><td>-<\/td><td>85.7<\/td><td>[66.1-94.4]<\/td><td><\/td><\/tr><tr><td>X.c Malignant gonadal germ cell tumors<\/td><td>100.0<\/td><td>-<\/td><td>100.0<\/td><td>-<\/td><td>100.0<\/td><td>-<\/td><td>96.0<\/td><td>[92.1-98.0]<\/td><td><\/td><\/tr><tr><td>XI. Other malignant epithelial neoplasms and malignant melanomas<\/td><td>96.9<\/td><td>[79.8-99.6]<\/td><td>87.5<\/td><td>[79.0-92.7]<\/td><td>93.1<\/td><td>[88.6-95.8]<\/td><td>94.0<\/td><td>[91.8-95.6]<\/td><td><\/td><\/tr><tr><td>XI.b Thyroid carcinomas<\/td><td>100.0<\/td><td>-<\/td><td>100.0<\/td><td>-<\/td><td>98.8<\/td><td>[91.5-99.8]<\/td><td>98.9<\/td><td>[96.6-99.6]<\/td><td><\/td><\/tr><tr><td>XI.d Malignant melanomas<\/td><td>100.0<\/td><td>-<\/td><td>81.0<\/td><td>[62.5-91.0]<\/td><td>89.3<\/td><td>[76.2-95.4]<\/td><td>88.3<\/td><td>[79.9-93.4]<\/td><td><\/td><\/tr><tr><td>XII. Other and unspecified malignant neoplasms<\/td><td>100.0<\/td><td>-<\/td><td>76.5<\/td><td>[58.4-87.5]<\/td><td>85.7<\/td><td>[33.4-97.9]<\/td><td>58.6<\/td><td>[26.7-80.6]<\/td><td><\/td><\/tr><tr><td>All cancers (excluding Langherhans cell histiocytosis)<\/td><td>81.3<\/td><td>[79.9-82.7]<\/td><td>83.3<\/td><td>[82.6-84.1]<\/td><td>82.6<\/td><td>[81.7-83.4]<\/td><td>83.7<\/td><td>[82.9-84.5]<\/td><td>**<\/td><\/tr><tr><td>Langherhans cell histiocytosis<\/td><td>87.2<\/td><td>[73.8-94.1]<\/td><td>96.4<\/td><td>[86.2-99.1]<\/td><td>100.0<\/td><td>-<\/td><td>100.0<\/td><td>-<\/td><td><\/td><\/tr><tr><td>All cancers (including Langherhans cell histiocytosis)<\/td><td>81.4<\/td><td>[80.0-82.8]<\/td><td>83.4<\/td><td>[82.7-84.1]<\/td><td>82.6<\/td><td>[81.7-83.4]<\/td><td>83.8<\/td><td>[82.9-84.6]<\/td><td>**<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>** pvalue <0.01<\/td><td> * pvalue < 0.05<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li>\t\t\t\t\t\t\t<li class=\"item\">\n\t\t\t\t\t\t\t\t<div class=\"heading\"><h6><span class='icon dce-accordion-icon accordion-icon-left'><i aria-hidden=\"true\" class=\"fas fa-angle-right\"><\/i><\/span><span class='icon-active dce-accordion-icon accordion-icon-left'><\/span>\n\t\t<span class=\"accordion-title accordion-title accordion-title\">\n\t\t\tTemporal evolution of the 5-year survival rate of childhood cancers between 2000 and 2016, estimated by diagnostic group and period.\t\t<\/span>\n\t\t<\/h6><\/div>\n\t\t\t\t\t\t\t\t<div>\n\t\t\t\t\t\t\t<span class=\"repeater-item elementor-repeater-item-c6a9103\"><table><thead><th>Diagnostic groups and subgroups<\/th><th>2000-2004<\/th><th><\/th><th>2005-2009<\/th><th><\/th><th>2010-2016<\/th><th><\/th><th>p<\/th><\/thead><tbody><tr><td>I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases<\/td><td>83.0<\/td><td>[81.4-84.4]<\/td><td>87.0<\/td><td>[85.6-88.3]<\/td><td>87.6<\/td><td>[86.4-88.7]<\/td><td>**<\/td><\/tr><tr><td>I.a Lymphoid leukemias<\/td><td>89.2<\/td><td>[87.7-90.5]<\/td><td>91.0<\/td><td>[89.6-92.2]<\/td><td>89.9<\/td><td>[88.6-91.0]<\/td><td><\/td><\/tr><tr><td>I.b Acute myeloid leukemias<\/td><td>59.4<\/td><td>[54.3-64.1]<\/td><td>71.4<\/td><td>[66.2-76.0]<\/td><td>78.2<\/td><td>[74.2-81.7]<\/td><td>**<\/td><\/tr><tr><td>II. Lymphomas and reticuloendothelial neoplasms<\/td><td>93.6<\/td><td>[91.8-94.9]<\/td><td>93.2<\/td><td>[91.4-94.7]<\/td><td>95.8<\/td><td>[94.6-96.8]<\/td><td>*<\/td><\/tr><tr><td>II.a Hodgkin lymphomas<\/td><td>96.7<\/td><td>[94.5-98.0]<\/td><td>96.7<\/td><td>[94.4-98.1]<\/td><td>99.3<\/td><td>[98.2-99.7]<\/td><td>**<\/td><\/tr><tr><td>II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)<\/td><td>91.2<\/td><td>[87.3-93.9]<\/td><td>86.6<\/td><td>[82.1-90.1]<\/td><td>90.5<\/td><td>[87.0-93.2]<\/td><td><\/td><\/tr><tr><td>II.c Burkitt lymphomas<\/td><td>91.4<\/td><td>[87.3-94.3]<\/td><td>95.2<\/td><td>[91.4-97.3]<\/td><td>95.4<\/td><td>[92.3-97.3]<\/td><td><\/td><\/tr><tr><td>III. CNS and miscellaneous intracranial and intraspinal neoplasms<\/td><td>71.1<\/td><td>[69.1-73.0]<\/td><td>74.7<\/td><td>[72.8-76.5]<\/td><td>76.5<\/td><td>[75.0-78.0]<\/td><td>**<\/td><\/tr><tr><td>III.a Ependymomas and choroid plexus tumors<\/td><td>62.5<\/td><td>[55.3-68.9]<\/td><td>77.6<\/td><td>[71.2-82.8]<\/td><td>80.8<\/td><td>[75.3-85.1]<\/td><td>**<\/td><\/tr><tr><td>III.b Astrocytomas<\/td><td>86.9<\/td><td>[84.4-89.1]<\/td><td>88.1<\/td><td>[85.5-90.2]<\/td><td>86.4<\/td><td>[84.3-88.2]<\/td><td><\/td><\/tr><tr><td>III.c Intracranial and intraspinal embryonal tumors<\/td><td>52.2<\/td><td>[47.3-56.9]<\/td><td>55.4<\/td><td>[50.4-60.1]<\/td><td>59.0<\/td><td>[54.6-63.1]<\/td><td><\/td><\/tr><tr><td>III.d Other gliomas<\/td><td>35.8<\/td><td>[30.2-41.5]<\/td><td>39.5<\/td><td>[34.0-44.9]<\/td><td>40.2<\/td><td>[35.4-45.0]<\/td><td><\/td><\/tr><tr><td>III.e Other specified intracranial and intraspinal neoplasms<\/td><td>93.8<\/td><td>[90.6-95.9]<\/td><td>95.8<\/td><td>[93.3-97.4]<\/td><td>95.7<\/td><td>[93.7-97.1]<\/td><td><\/td><\/tr><tr><td>IV. Neuroblastomas and other peripheral nervous cell tumors<\/td><td>72.7<\/td><td>[69.3-75.8]<\/td><td>75.3<\/td><td>[72.0-78.3]<\/td><td>80.3<\/td><td>[77.5-82.9]<\/td><td>**<\/td><\/tr><tr><td>IV.a Neuroblastomas and ganglioneuroblastomas<\/td><td>72.5<\/td><td>[69.1-75.7]<\/td><td>75.2<\/td><td>[71.8-78.2]<\/td><td>80.1<\/td><td>[77.2-82.7]<\/td><td>**<\/td><\/tr><tr><td>V. Retinoblastomas<\/td><td>99.2<\/td><td>[96.8-99.8]<\/td><td>98.5<\/td><td>[96.0-99.4]<\/td><td>100.0<\/td><td>-<\/td><td><\/td><\/tr><tr><td>VI. Renal tumors<\/td><td>91.6<\/td><td>[88.7-93.7]<\/td><td>92.9<\/td><td>[90.3-94.9]<\/td><td>93.3<\/td><td>[91.0-95.0]<\/td><td><\/td><\/tr><tr><td>VI.a Nephroblastomas and other nonepithelial renal tumors<\/td><td>92.0<\/td><td>[89.1-94.2]<\/td><td>92.9<\/td><td>[90.3-94.9]<\/td><td>93.7<\/td><td>[91.4-95.4]<\/td><td><\/td><\/tr><tr><td>VII. Hepatic tumors<\/td><td>83.1<\/td><td>[72.2-90.0]<\/td><td>78.3<\/td><td>[68.7-85.3]<\/td><td>87.0<\/td><td>[79.8-91.7]<\/td><td><\/td><\/tr><tr><td>VII.a Hepatoblastomas<\/td><td>86.9<\/td><td>[75.5-93.2]<\/td><td>82.0<\/td><td>[71.6-88.9]<\/td><td>87.1<\/td><td>[79.5-92.0]<\/td><td><\/td><\/tr><tr><td>VIII. Malignant bone tumors<\/td><td>74.6<\/td><td>[70.0-78.5]<\/td><td>75.2<\/td><td>[70.7-79.1]<\/td><td>73.1<\/td><td>[68.9-76.8]<\/td><td><\/td><\/tr><tr><td>VIII.a Osteosarcomas<\/td><td>73.1<\/td><td>[66.3-78.7]<\/td><td>74.1<\/td><td>[66.9-79.9]<\/td><td>68.0<\/td><td>[61.5-73.6]<\/td><td><\/td><\/tr><tr><td>VIII.c Ewing tumors and related bone sarcomas<\/td><td>74.7<\/td><td>[67.4-80.6]<\/td><td>74.1<\/td><td>[67.4-79.7]<\/td><td>77.0<\/td><td>[71.1-81.9]<\/td><td><\/td><\/tr><tr><td>IX. Soft tissue and other extraosseous sarcomas<\/td><td>69.0<\/td><td>[64.8-72.7]<\/td><td>73.5<\/td><td>[69.7-77.0]<\/td><td>74.8<\/td><td>[71.4-77.8]<\/td><td><\/td><\/tr><tr><td>IX.a Rhabdomyosarcomas<\/td><td>67.4<\/td><td>[61.6-72.4]<\/td><td>74.3<\/td><td>[69.0-78.8]<\/td><td>76.6<\/td><td>[71.9-80.5]<\/td><td><\/td><\/tr><tr><td>IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms<\/td><td>74.4<\/td><td>[57.6-85.3]<\/td><td>80.0<\/td><td>[64.0-89.5]<\/td><td>87.9<\/td><td>[76.1-94.0]<\/td><td><\/td><\/tr><tr><td>IX.d Other specified soft tissue sarcomas<\/td><td>72.1<\/td><td>[64.6-78.3]<\/td><td>71.3<\/td><td>[63.9-77.4]<\/td><td>69.6<\/td><td>[62.9-75.2]<\/td><td><\/td><\/tr><tr><td>IX.e Unspecified soft tissue sarcomas<\/td><td>60.0<\/td><td>[43.2-73.3]<\/td><td>70.7<\/td><td>[54.3-82.2]<\/td><td>70.3<\/td><td>[56.4-80.5]<\/td><td><\/td><\/tr><tr><td>X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads<\/td><td>92.3<\/td><td>[88.9-94.7]<\/td><td>93.1<\/td><td>[89.8-95.3]<\/td><td>96.5<\/td><td>[94.3-97.9]<\/td><td><\/td><\/tr><tr><td>X.a Intracranial and intraspinal germ cell tumors<\/td><td>91.8<\/td><td>[85.3-95.5]<\/td><td>94.0<\/td><td>[87.9-97.1]<\/td><td>96.5<\/td><td>[92.4-98.4]<\/td><td><\/td><\/tr><tr><td>X.b Malignant extracranial and extragonadal germ cell tumors<\/td><td>92.2<\/td><td>[84.4-96.2]<\/td><td>85.1<\/td><td>[76.2-90.9]<\/td><td>95.3<\/td><td>[89.1-98.0]<\/td><td>*<\/td><\/tr><tr><td>X.c Malignant gonadal germ cell tumors<\/td><td>95.7<\/td><td>[90.0-98.2]<\/td><td>98.3<\/td><td>[93.2-99.6]<\/td><td>99.2<\/td><td>[94.7-99.9]<\/td><td><\/td><\/tr><tr><td>XI. Other malignant epithelial neoplasms and malignant melanomas<\/td><td>92.8<\/td><td>[89-95.4]<\/td><td>93.3<\/td><td>[89.6-95.7]<\/td><td>93.3<\/td><td>[90.5-95.4]<\/td><td><\/td><\/tr><tr><td>XI.b Thyroid carcinomas<\/td><td>98.2<\/td><td>[93.0-99.5]<\/td><td>100.0<\/td><td>-<\/td><td>98.5<\/td><td>[93.9-99.6]<\/td><td><\/td><\/tr><tr><td>XI.d Malignant melanomas<\/td><td>84.1<\/td><td>[71.6-91.4]<\/td><td>87.2<\/td><td>[73.6-94.0]<\/td><td>90.2<\/td><td>[80.3-95.3]<\/td><td><\/td><\/tr><tr><td>XII. Other and unspecified malignant neoplasms<\/td><td>57.1<\/td><td>[28.4-78.0]<\/td><td>90.0<\/td><td>[65.6-97.4]<\/td><td>81.8<\/td><td>[63.9-91.4]<\/td><td><\/td><\/tr><tr><td>All cancers (excluding Langherhans cell histiocytosis)<\/td><td>80.8<\/td><td>[79.9-81.6]<\/td><td>83.3<\/td><td>[82.5-84.1]<\/td><td>84.6<\/td><td>[83.9-85.2]<\/td><td>**<\/td><\/tr><tr><td>Langherhans cell histiocytosis<\/td><td>94.3<\/td><td>[79.0-98.5]<\/td><td>97.1<\/td><td>[80.9-99.6]<\/td><td>89.1<\/td><td>[75.7-95.3]<\/td><td><\/td><\/tr><tr><td>All cancers (including Langherhans cell histiocytosis)<\/td><td>80.8<\/td><td>[80.0-81.7]<\/td><td>83.3<\/td><td>[82.5-84.1]<\/td><td>84.6<\/td><td>[83.9-85.3]<\/td><td>**<\/td><\/tr><tr><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>** pvalue <0.01; * pvalue < 0.05<\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/span><\/div><\/li><\/ul><\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Childhood cancer is a rare disease, affecting approximately 1,800 children under the age of 15 each year in metropolitan France (about one newborn out of 440 will be diagnosed with cancer before the age of 15). The distribution of childhood cancers by histological type and location is very different from that of adults, notably with [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5256,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-3341","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/3341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=3341"}],"version-history":[{"count":12,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/3341\/revisions"}],"predecessor-version":[{"id":5634,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/3341\/revisions\/5634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/media\/5256"}],"wp:attachment":[{"href":"https:\/\/rnce.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=3341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}